Publication:
Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients

dc.contributor.authorsGiral, A; Celikel, CA; Ozdogan, O; Tozun, N; Ulusoy, NB; Kalayci, C
dc.date.accessioned2022-03-12T17:19:34Z
dc.date.accessioned2026-01-11T06:43:49Z
dc.date.available2022-03-12T17:19:34Z
dc.date.issued2005
dc.description.abstractBackground: Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment. It has been also shown that the treatment with proton pump inhibitors produces lower intragastric pH after H. pylori eradication in subjects with peptic ulcer and healthy individuals. The aim of the present study was to test the hypothesis of whether the efficacy of lansoprazole is reduced after the eradication of H. pylori in GERD patients with peptic esophagitis. Methods: Eight-hour intragastric pH recordings were performed before and after an 8-day course of lansoprazole (30 mg once daily) in 10 H. pylori-positive male patients with reflux esophagitis and were repeated after the H. pylori eradication. Intragastric acidity was measured by using an antimony electrode placed 10 cm below the cardia. Results: Baseline median preprandial, post-prandial, total intragastric pH and the percentage of time with pH < 3 were not different before and after H. pylori eradication without lansoprazole treatment. During lansoprazole treatment, median post-prandial intragastric pH was lower (4 vs 2.7; P < 0.05) and the percentage of time with pH < 3 was longer (3.4%vs 41.8%; P < 0.05) after H. pylori eradication. Median total intragastric pH tended to be lower after eradication but no difference was found in preprandial median pH. Conclusions: In patients with reflux esophagitis treated with lansoprazole, intragastric pH increased significantly when H. pylori was present, especially in the post-prandial period, whereas baseline pH remained unchanged after H. pylori eradication. (C) 2005 Blackwell Publishing Asia Pty Ltd.
dc.identifier.doi10.1111/j.1440-1746.2005.03896.x
dc.identifier.eissn1440-1746
dc.identifier.issn0815-9319
dc.identifier.pubmed16336449
dc.identifier.urihttps://hdl.handle.net/11424/228126
dc.identifier.wosWOS:000233147700014
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectgastritis
dc.subjectgastroesophageal reflux disease
dc.subjectHelicobacter pylori
dc.subjectlansoprazole
dc.subjectacid secretion
dc.subjectGASTRIC-ACID-SECRETION
dc.subjectINTRAGASTRIC PH
dc.subjectINFECTION
dc.subjectOMEPRAZOLE
dc.subjectESOPHAGITIS
dc.subjectBREAKTHROUGH
dc.subjectAUGMENTS
dc.subjectINJURY
dc.subjectCURE
dc.titleImpact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage1891
oaire.citation.issue12
oaire.citation.startPage1886
oaire.citation.titleJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
oaire.citation.volume20

Files